Frequently Asked Questions

• The ultimate goal in developing RTX-240 is to provide patients a safe and effective new cancer treatment option.
• RTX-240 is an investigational cellular therapy designed to activate the immune system to fight cancer.

The purpose of the clinical trial is to find out whether RTX-240 is safe, how much RTX-240 needs to be given for it to be effective and how often it should be given to be effective.

Examples of solid tumors include, but are not limited to, breast cancer, kidney cancer, melanoma, non-small cell lung cancer, small cell lung cancer, squamous cell cancer and more.

RTX-240 is given intravenously (IV), which means into a vein by a trained medical professional.

Participants who join the trial will have a doctor’s exam, blood tests and additional lab work before receiving RTX-240.

• Once participants receive the first dose of RTX-240, they will be closely observed and continue to be monitored over the treatment period until disease progression or undesirable toxicities.
• After the last dose of RTX-240, the patient will participate in an end-of-treatment visit within 30 days of the last dose given.
• Following the conclusion of study participation, patients will be monitored for up to 15 years for any potential incidence of long-term effects of RTX-240.
• Long-term follow up assessments will occur every 30 days for the first two months and then annually thereafter.

• Patients cannot receive other investigational anti-cancer treatments while receiving doses of RTX-240.
• Once the final dose has been administered and the end of treatment visit has taken place, patients may go on to receive additional anti-cancer treatments.
• Please speak with your doctor about any questions.

• Although participants cannot be enrolled in other clinical trials while participating in the RTX-240 clinical trial, we do not anticipate that participation in the RTX-240 clinical trial will disqualify you from taking part in other future clinical trials.
• It is important to note, however, that each trial has its own criteria regarding who can participate. Patients who participate in the Phase 1/2 trial for RTX-240 may also be able to participate in future RTX-240 trials, pending results of this trial.
• Please speak with your doctor about any questions.

• Rubius Therapeutics plans to investigate RTX-240 in specific types of cancers that will be determined by the results of the Phase 1 portion of the RTX-240 clinical trial.
• Additionally, Rubius Therapeutics is evaluating RTX-240 in relapsed and refractory acute myeloid leukemia.

All necessary travel and lodging costs related to trial participation will be covered by Rubius Therapeutics; the process for patient reimbursement may vary by trial site.

Rubius Therapeutics is committed to the safety of all clinicians and patients participating in the trial. Each trial site has its own procedures to minimize risk of COVID-19 transmission. If you have any questions, please speak directly with your physician.